In addition, elevated tumor SOX2 resulted in 36% reduction in risk for all NSCLC patients at Cox univariate analysis (hazards ratio-HR = 0.64 confidence interval-CI (0.46,0.91), p = 0.01). This evidence concerns the gene SOX2 and neoplasm.